Pharmaceutical composition containing an endocytic motif and protein transduction domains for preventing or treating cancer

Patent metadata

Field	Value
Publication number	US-9617304-B2
Application number	US-201214002600-A
Country	US
Kind code	B2
Filing date	Mar 2, 2012
Priority date	Mar 2, 2011
Publication date	Apr 11, 2017
Grant date	Apr 11, 2017

Abstract

The present invention relates to a novel endocytic motif, and in particular, to a fusion polypeptide including the motif represented by an amino acid sequence of SEQ ID NO. 1 and a protein transduction domain, a pharmaceutical composition for preventing or treating cancer including the same, and a method for treating cancer including the step of administering the composition. The present invention shows the effects of suppressing metastasis, infiltration, angiogenesis, and growth of cancer by specifically inhibiting c-Met endocytosis and effectively inhibiting HGF/c-Met signaling pathway associated with metastasis and growth of various types of cancer cells. Therefore, the present invention can be applied to an anticancer agent for various types of cancer.

First claim

What is claimed is:

1. A method for treating cancer, comprising administering a fusion polypeptide to a subject having cancer or being at risk of having cancer, wherein the fusion polypeptide is represented by the amino acid sequence of SEQ ID NO: 10, wherein the cancer is one or more selected from the group consisting of hepatocellular carcinoma and cervical cancer.

2. The method according to claim 1 , wherein the treatment is performed by inhibiting metastasis or growth of cancer.

3. The method according to claim 1 , wherein the fusion polypeptide inhibits endocytosis of one or more selected from the group consisting of c-Met, phosphorylated c-Met and c-Met bound to hepatocyte growth factor (HGF).

4. The method according to claim 1 , wherein the fusion polypeptide inhibits hepatocyte growth factor (HGF)-induced autophosphorylation of c-Met.

5. A method for inhibiting metastasis of cancer, comprising administering a fusion polypeptide to a subject having cancer, wherein the fusion polypeptide is represented by the amino acid sequence of SEQ ID NO: 10, wherein the cancer is one or more selected from the group consisting of hepatocellular carcinoma and cervical cancer.

6. A method for inhibiting endocytosis of one or more selected from the group consisting of c-Met, phosphorylated c-Met and c-Met bound to hepatocyte growth factor (HGF), comprising administering a fusion polypeptide to a subject, wherein the fusion polypeptide is represented by the amino acid sequence of SEQ ID NO: 10.

Assignees

• Park Young Woo
• Jo Ki Won
• Cho Kyu Won
• Park Ji Hyun
• Hyun Soon Sil
• Park Yun Jung
• Korea Res Inst Bioscience & Biotechnology

Inventors

• Park Young Woo
• Jo Ki Won
• Cho Kyu Won
• Park Ji Hyun
• Hyun Soon Sil
• Park Yun Jung

Classifications

• C07K14/4753

  Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II · CPC title

• C07K7/08 Primary

  having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C07K2319/10

  containing a tag for extracellular membrane crossing, e.g. TAT or VP22 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title